Edesa Biotech financials
$3.56−2.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Jun 30 | Q2 '26 Mar 31 | Q1 '26 Dec 31 | Q4 '25 Sep 30 | Q3 '25 Jun 30 | Q2 '25 Mar 31 | Q1 '25 Dec 31 | Q4 '24 Sep 30 | Q3 '24 Jun 30 | Q2 '24 Mar 31 | Q1 '24 Dec 31 | Q4 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$5.5M | -$4.3M | -$2.3M | -$2.5M | -$1.9M | -$1.6M | -$1.9M | -$1.0M | -$1.9M | -$2.2M | -$1.9M | -$2.4M |
| Net income | -$5.4M | -$4.2M | -$2.2M | -$2.2M | -$1.7M | -$1.6M | -$1.6M | -$962.1K | -$1.7M | -$1.9M | -$1.7M | -$1.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.60 | $-0.49 | $-0.28 | $-0.32 | $-0.25 | $-0.30 | $-0.48 | $-0.30 | $-0.52 | $-0.58 | $-0.54 | $-0.57 |
| EBITDA | -$5.5M | -$4.3M | -$2.3M | -$2.4M | -$1.9M | -$1.6M | -$1.9M | -$960.2K | -$1.9M | -$2.2M | -$1.8M | -$2.3M |
| Operating cash flow | -$3.1M | -$2.0M | -$2.1M | -$1.7M | -$1.7M | -$2.4M | -$1.5M | -$967.0K | -$856.5K | -$1.7M | -$1.4M | -$1.5M |
| Free cash flow | -$3.1M | -$2.0M | -$2.1M | -$1.7M | -$1.7M | -$2.4M | -$1.5M | -$967.0K | -$856.5K | -$1.7M | -$1.4M | -$1.5M |
| Diluted shares | 9.0M | 8.5M | 8.0M | 7.0M | 7.0M | 5.3M | 3.3M | 3.2M | 3.2M | 3.2M | 3.1M | 3.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.3M | $10.0M | $12.1M | $10.8M | $12.4M | $13.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $12.7M | $12.4M | $14.7M | $13.5M | $14.8M | $16.5M |
| Total liabilities | $3.9M | $2.2M | $756.2K | $1.1M | $672.7K | $914.7K |
| Shareholders' equity | $8.8M | $10.2M | $4.7M | $12.5M | $14.1M | $15.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology